MedTrace Logo

Diphenylcyclopropenone (DPCP) as a Depigmenting Therapy in Extensive Vitiligo

NCT04775979 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-04-11

No results posted yet for this study

Summary

The aim of the present work is to evaluate the efficacy and safety of diphenylcyclopropenone (DPCP) as a depigmenting therapy in extensive Vitiligo.

Conditions

  • Vitiligo

Interventions

DRUG

diphenylcyclopropenone (DPCP)

Depigmenting agent

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Marwa MA Abdallah · Ain Shams University

  • Rania M Elhusseiny · Ain Shams University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-17
Primary Completion
2021-07-30
Completion
2021-08-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04775979 on ClinicalTrials.gov